18 July 2024EMAAbecma / Breyanzi / Carvykti / Kymriah / Tecartus / Yescarta: adverse eventAdverse eventMedicine safety communications
17 July 2024EMAHydroxyprogesterone caproate: post-authorisation measurePost-authorisation measureMedicine safety communications
19 February 2024EMAValproate: post-authorisation measurePost-authorisation measureMedicine safety communications
9 February 2024EMAPseudoephedrine: referral - article 31Referral - Article 31Medicine safety communications
8 November 2023EMAOmega-3 fatty acid ethyl esters: adverse eventAdverse eventMedicine safety communications
1 November 2023EMATopiramate / phentermine: restriction of indicationRestriction of indicationMedicine safety communications
17 August 2023EMARoActemra / Hemlibra / Herceptin / Kadcyla / MabThera / Phesgo / Tecentriq: quality defectQuality defectMedicine safety communications
16 June 2023EMAGavreto: adverse event;post-authorisation measureAdverse event;Post-authorisation measureMedicine safety communications
15 June 2023EMAAdakveo: lack of effect;referral - article 20 procedureLack of effect;Referral - Article 20 procedureMedicine safety communications
8 June 2023EMAFluoroquinolones: post-authorisation measurePost-authorisation measureMedicine safety communications